BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1144 related articles for article (PubMed ID: 24216225)

  • 1. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
    Agulnik M
    Med Oncol; 2012 Dec; 29(4):2481-91. PubMed ID: 22252310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.
    Markovic A; Chung CH
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1149-59. PubMed ID: 23098115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Role of Dacomitinib in Head and Neck Cancer.
    Elicin O; Ozsahin M
    Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
    Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
    Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-targeted therapies in the post-genomic era.
    Xu MJ; Johnson DE; Grandis JR
    Cancer Metastasis Rev; 2017 Sep; 36(3):463-473. PubMed ID: 28866730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
    De Pauw I; Lardon F; Van den Bossche J; Baysal H; Fransen E; Deschoolmeester V; Pauwels P; Peeters M; Vermorken JB; Wouters A
    Mol Oncol; 2018 Jun; 12(6):830-854. PubMed ID: 29603584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.